| Age (median, months) | | 46.5 (26,71.5) | | |
| ≥54 months (n, %) | YES | 37(66) | 63.9% | 0.007 |
| | No | 19(34) | 25% | |
| PRETEXT (n, %) | | | | 0.089 |
| | I | 0 | 0 | |
| | II | 26(46) | 65.4% | |
| | III | 26(46) | 38.5% | |
| | IV | 4(8) | 25% | |
| SIOPEL risk stratification (n, %) | | | | 0.239 |
| | SR | 27(48) | 59.9% | |
| | HR | 29(52) | 40.1% | |
| Tumor size (median, cm2) | | 100.84 (69.76,142.31) | | |
| Initial serum AFP (median, ng/ml) | | 31,125 (5434,74,250) | | |
| Non-recurrent (n) | | 28 | | |
| Recurrent (n) | | 28 | | |
| Site of tumour recurrence (n, %) | Local | 21(75) | | |
| | Lung metastasis | 7(25) | | |
| Prognoses (n, %) | Survive | 46(82) | | |
| | Death | 7(13) | | |
| | Lost to follow up | 3(5) | | |
| follow-up time (median, months) | | 44 | | |
